GB2186885B - Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas - Google Patents

Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas

Info

Publication number
GB2186885B
GB2186885B GB8703700A GB8703700A GB2186885B GB 2186885 B GB2186885 B GB 2186885B GB 8703700 A GB8703700 A GB 8703700A GB 8703700 A GB8703700 A GB 8703700A GB 2186885 B GB2186885 B GB 2186885B
Authority
GB
United Kingdom
Prior art keywords
human
carcinomas
certain
antigen
small cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB8703700A
Other languages
English (en)
Other versions
GB8703700D0 (en
GB2186885A (en
Inventor
Karl Erik Hellstrom
Joseph P Brown
Ingegerd Hellstrom
Hans Marquard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of GB8703700D0 publication Critical patent/GB8703700D0/en
Publication of GB2186885A publication Critical patent/GB2186885A/en
Application granted granted Critical
Publication of GB2186885B publication Critical patent/GB2186885B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
GB8703700A 1986-02-26 1987-02-18 Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas Expired - Fee Related GB2186885B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/834,172 US5185432A (en) 1986-02-26 1986-02-26 Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas

Publications (3)

Publication Number Publication Date
GB8703700D0 GB8703700D0 (en) 1987-03-25
GB2186885A GB2186885A (en) 1987-08-26
GB2186885B true GB2186885B (en) 1990-10-03

Family

ID=25266276

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8703700A Expired - Fee Related GB2186885B (en) 1986-02-26 1987-02-18 Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas

Country Status (28)

Country Link
US (1) US5185432A (enExample)
JP (1) JPS62220197A (enExample)
KR (2) KR870008026A (enExample)
CN (1) CN87100927A (enExample)
AT (1) AT400577B (enExample)
AU (1) AU612967B2 (enExample)
BE (1) BE1000611A5 (enExample)
CA (1) CA1312025C (enExample)
CH (1) CH675880A5 (enExample)
DD (2) DD276165A5 (enExample)
DE (1) DE3705276A1 (enExample)
DK (1) DK98187A (enExample)
ES (1) ES2004245A6 (enExample)
FI (1) FI870764A7 (enExample)
FR (1) FR2596062B1 (enExample)
GB (1) GB2186885B (enExample)
GR (1) GR870294B (enExample)
IE (1) IE60286B1 (enExample)
IT (1) IT1203511B (enExample)
LU (1) LU86786A1 (enExample)
NL (1) NL8700415A (enExample)
NO (1) NO174719C (enExample)
NZ (1) NZ219338A (enExample)
OA (1) OA08485A (enExample)
PT (1) PT84370B (enExample)
SE (2) SE467988B (enExample)
YU (1) YU46189B (enExample)
ZA (1) ZA869494B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3531301A1 (de) * 1985-09-02 1987-03-05 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte glykoproteine, verfahren zu ihrer herstellung sowie ihre verwendung
JPH0813840B2 (ja) * 1987-03-31 1996-02-14 協和醗酵工業株式会社 抗ヒト肺腺癌単クロ−ン性抗体
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
DE69831522T2 (de) 1997-03-03 2006-06-14 Amersham Biosciences Uk Ltd In-situ Zellextraktion und Assay-Verfahren
DE19725133A1 (de) * 1997-06-13 1998-12-17 Micromet Ges Fuer Biomedizinis Nachweis von seltenen Zellen
US20050089918A1 (en) * 1998-02-23 2005-04-28 Amersham Biosciences Uk Limited In-situ cell extraction and assay method
US6117981A (en) * 1999-06-03 2000-09-12 Cytoclonal Pharmaceutics, Inc. Hybridomas for lung cancer marker and monoclonal antibodies thereof
JP2003512819A (ja) * 1999-09-03 2003-04-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｂ７様ポリヌクレオチド、ポリペプチドおよび抗体
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
TWI317285B (en) * 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
CN101724072B (zh) * 2008-10-27 2013-10-09 谷为岳 一种抗肿瘤的单克隆抗体的序列及应用
GB0916686D0 (en) * 2009-09-23 2009-11-04 Univ Manchester Metropolitan Treatment of cancer
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
WO2012036094A1 (ja) * 2010-09-17 2012-03-22 独立行政法人産業技術総合研究所 肺癌鑑別マーカー
CN102391992B (zh) * 2011-11-03 2012-08-29 潘世扬 抗人非小细胞肺癌单克隆抗体及其应用
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
CN111662371B (zh) * 2020-04-30 2023-07-04 美康生物科技股份有限公司 细胞角蛋白19片段抗原及其制备方法和应用
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125928A2 (en) * 1983-05-18 1984-11-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Monoclonal antibodies against non small cell lung cancer
WO1986002735A1 (en) * 1984-11-02 1986-05-09 Oncogen Monoclonal antibodies and antigens for human non-small cell lung carcinomas

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858371B (en) * 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125928A2 (en) * 1983-05-18 1984-11-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Monoclonal antibodies against non small cell lung cancer
WO1986002735A1 (en) * 1984-11-02 1986-05-09 Oncogen Monoclonal antibodies and antigens for human non-small cell lung carcinomas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH (198 *

Also Published As

Publication number Publication date
ES2004245A6 (es) 1988-12-16
BE1000611A5 (fr) 1989-02-21
YU25787A (en) 1990-12-31
DE3705276A1 (de) 1987-08-27
KR870008026A (ko) 1987-09-23
YU46189B (sh) 1993-05-28
IT8719491A0 (it) 1987-02-25
GR870294B (en) 1987-06-30
PT84370A (en) 1987-03-01
NL8700415A (nl) 1987-09-16
KR880010438A (ko) 1988-10-08
LU86786A1 (fr) 1987-09-15
IE60286B1 (en) 1994-06-29
FI870764A0 (fi) 1987-02-23
ZA869494B (en) 1987-10-28
JPS62220197A (ja) 1987-09-28
PT84370B (pt) 1989-11-10
OA08485A (fr) 1988-07-29
NO174719B (no) 1994-03-14
GB8703700D0 (en) 1987-03-25
DK98187A (da) 1987-08-27
CH675880A5 (enExample) 1990-11-15
ATA43587A (de) 1995-06-15
NO174719C (no) 1994-06-22
US5185432A (en) 1993-02-09
NO870770D0 (no) 1987-02-25
CN87100927A (zh) 1988-10-05
DK98187D0 (da) 1987-02-25
SE9201529A0 (sv) 1992-05-14
SE9201529D0 (sv) 1992-05-14
SE8700805D0 (sv) 1987-02-25
KR900006338B1 (ko) 1990-08-28
AU612967B2 (en) 1991-07-25
CA1312025C (en) 1992-12-29
SE467988B (sv) 1992-10-12
FI870764A7 (fi) 1987-08-27
SE8700805L (sv) 1987-10-22
AT400577B (de) 1996-01-25
NO870770L (no) 1987-08-27
AU6927287A (en) 1987-08-27
IT1203511B (it) 1989-02-15
FR2596062B1 (fr) 1990-06-08
DD266028A5 (de) 1989-03-22
DD276165A5 (de) 1990-02-14
NZ219338A (en) 1991-11-26
GB2186885A (en) 1987-08-26
FR2596062A1 (fr) 1987-09-25
IE870487L (en) 1987-08-26

Similar Documents

Publication Publication Date Title
NZ232554A (en) 100,000 dalton tumour cell glycoprotein antigen (l45), monoclonal antibodies thereto and medicaments
YU25787A (en) Cell
HUT42637A (en) Monoclonic antibodies and antigens for treating human, non-little-cellular carcinomas of lung
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
ATE91132T1 (de) Monoklonale antikoerper fuer humane lungenkarzinome des ''nicht-kleine-zellen''-typs.
ES2012997A6 (es) Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal.
ATE61734T1 (de) Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
NO914094L (no) Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer
Shitara et al. Glycoproteins Distinguishing Non-Small Cell From Small Cell Human Lung Car-cinoma Recognized by Monoclonal An-tibody 43-9F. Pettijohn, DE, Stranahan, PL, Due

Legal Events

Date Code Title Description
711B Application made for correction of error (sect. 117/77)
711E Case decided by the comptroller ** specification corrected (sect. 117/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19970218